心血管疾病在被诊断为乳腺癌的女性中占所有因素致死率的10％，其原因是多方面的。许多处于乳腺癌风险或诊断状态的女性正在接受内分泌调节治疗。因此，了解激素疗法对乳腺癌患者心血管结局的影响非常重要，以减轻任何不良反应并确定最容易受到风险的人，以便积极管理。在这里，我们讨论这些药物的病理生理学、它们对心血管系统的影响以及它们与心血管风险关联的最新证据。在治疗期间，他托利芬似乎具有心脏保护作用，但长期没有这种效果，AI对心血管结果的影响仍有争议。心力衰竭结果仍未得到充分研究，女性使用促性腺释放激素激动剂（GNRHa）的心血管影响需要进一步研究，特别是因为来自前列腺癌男性的数据表明GNRHa使用者存在心脏事件风险增加。需要更好地了解激素疗法对乳腺癌患者心血管结局的影响。在这个领域的进一步研究领域包括开发证据，以更好地定义预防和筛选心血管影响的最佳方法以及使用激素治疗的患者的风险因素。 © 2023作者（S），在Springer Science + Business Media，LLC的独家许可下，隶属于Springer Nature。

Cardiovascular disease accounts for up to 10% of all-cause mortality in women with a diagnosis of breast cancer, and the causes for this are multifaceted. Many women at risk of or with a diagnosis of breast cancer are on endocrine-modulating therapies. It is therefore important to understand the effect of hormone therapies on cardiovascular outcomes in breast cancer patients to mitigate against any adverse effects and to identify those most at risk so that they can be proactively managed. Here we discuss the pathophysiology of these agents, their effect on the cardiovascular system, and the latest evidence on their cardiovascular risks association.Tamoxifen appears to be cardioprotective during treatment but not over the longer term, while the effect of AIs on cardiovascular outcomes remains controversial. Heart failure outcomes remain understudied, and the cardiovascular effects of gonadotrophin-releasing hormone agonists (GNRHa) in women need further research, especially since data from men with prostate cancer have indicated an increased risk of cardiac events in GNRHa users. There remains a need for a greater understanding of the effects of hormone therapies on cardiovascular outcomes in breast cancer patients. Further areas of research in this area include developing evidence to better define the optimal preventive and screening methods for cardiovascular effects and the risk factors for patients on hormonal therapies.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.